Genmab A/S (GMAB)

Genmab Revenue

Genmab had revenue of $1.19B in the quarter ending September 30, 2026, with 16.14% growth. This brings the company's total for the last twelve months to $4.30B, up 23.61% year-over-year. In the year 2025, Genmab had annual revenue of $3.72B with 19.19% growth.

• Revenue (ttm): $4.30B
• Revenue Growth: +23.61%
• P/S Ratio: 8.08
• Revenue / Employee: $1,324,291
• Employees: 3,244
• Market Cap: 33.17B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• DARZALEX Royalties 2.44B 65.7%
• Kesimpta Royalties 443.00M 11.9%
• Net Product Sales 398.00M 10.7%
• Other Product Royalties 111.00M 3.0%
• TEPEZZA Royalties 105.00M 2.8%
• Milestone 97.00M 2.6%
• Collaboration 70.00M 1.9%
• Reimbursement 53.00M 1.4%

By Geography

Chart

• Denmark 3.33B 89.4%
• Japan 213.00M 5.7%
• United States 180.00M 4.8%
• Netherlands 1.00M 0.0%

Fiscal year ended Dec 31, 2025 See the full Genmab breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	3.72B	599.00M	19.19%
Dec 31, 2024	3.12B	731.00M	30.59%
Dec 31, 2023	2.39B	302.26M	14.48%
Dec 31, 2022	2.09B	800.56M	62.19%
Dec 31, 2021	1.29B	-372.56M	-22.45%
Dec 31, 2020	1.66B	854.43M	106.10%
Dec 31, 2019	805.32M	340.75M	73.35%
Dec 31, 2018	464.57M	83.44M	21.89%
Dec 31, 2017	381.13M	123.38M	47.87%
Dec 31, 2016	257.75M	92.65M	56.12%
Dec 31, 2015	165.10M	26.80M	19.38%
Dec 31, 2014	138.30M	15.94M	13.02%
Dec 31, 2013	122.37M	36.66M	42.78%
Dec 31, 2012	85.70M	24.59M	40.23%
Dec 31, 2011	61.12M	-43.27M	-41.45%
Dec 31, 2010	104.39M	-8.77M	-7.75%
Dec 31, 2009	113.16M	-16.25M	-12.56%
Dec 31, 2008	129.42M	25.30M	24.29%
Dec 31, 2007	104.12M	80.20M	335.29%
Dec 31, 2006	23.92M	8.33M	53.41%
Dec 31, 2005	15.59M	-	-

Data Source: Fiscal.ai Last updated: Nov 5, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error